Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Human Metabolome Technologies, Inc. specializes in metabolomics, providing advanced diagnostic and research solutions primarily in Japan and expanding into global markets. The company leverages proprietary technologies to analyze metabolic profiles, which are critical for personalized medicine and biomarker discovery.
The company generates revenue through a combination of service contracts for metabolomic analyses, sales of diagnostic kits, and partnerships with research institutions. Its competitive advantage lies in its proprietary technology for high-throughput metabolic profiling, which offers superior accuracy and speed compared to competitors.
Growth in demand for personalized medicine solutions
Expansion into new geographic markets, particularly in North America and Europe
Partnership announcements with pharmaceutical companies for drug development
Regulatory approvals for new diagnostic products
Technological disruption from emerging metabolomics competitors
Regulatory changes affecting diagnostic product approvals
Increased competition from established diagnostic firms expanding into metabolomics
Potential for new entrants leveraging advanced technologies
Low liquidity risk due to high current ratio (4.73)
Potential risks associated with reliance on a few large contracts
moderate - The demand for diagnostic services can be influenced by overall healthcare spending, which is correlated with GDP growth.
Low - The company has minimal debt, so rising interest rates do not significantly impact financing costs. However, higher rates could affect overall healthcare spending.
minimal - The company's low debt levels and strong cash flow reduce reliance on credit markets.
growth - The company's focus on innovative diagnostic solutions appeals to growth-oriented investors.
moderate - The stock has shown some volatility, with a 1-year return of -25.1%, indicating potential sensitivity to market conditions.
